Logo

People in the News: Dirk Evers, David Ghesquiere

Dec 05, 2013
Premium

Dirk Evers is VP of data operations at Molecular Health in Heidelberg, Germany. Previously, he was senior VP of informatics at the New York Genome Center and also served as the director of computational biology at Illumina. He holds a PhD in bioinformatics from Bielefeld University.

NanoString Technologies has appointed David Ghesquiere as senior VP of corporate and business development. Ghesquiere joins NanoString from Dendreon, where he served as senior VP of corporate and business development. He has also served executive roles with OSI Pharmaceuticals (acquired by Astellas) and Aventis Pharmaceuticals (acquired by Sanofi).

Filed under

Diagnostics
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.